Skip to main content
Clinical Trials/NCT04300816
NCT04300816
Completed
N/A

Efficacy of a Psychosocial Intervention to Improve Ability to Cope With Uncertainty in MS

University of Washington1 site in 1 country242 target enrollmentOctober 30, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
University of Washington
Enrollment
242
Locations
1
Primary Endpoint
Questionnaire: Level of MS Acceptance as measured by the Acceptance of Chronic Health Conditions, MS Version Questionnaire.
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this project is to test a brief, telephone-based psychological intervention, CBT-UT, to improve the ability to tolerate uncertainty-and thereby to reduce distress-in people with a recent diagnosis of Multiple Sclerosis (MS). There are three treatment arms for this study. Participants will receive either (1) CBT for Uncertainty Tolerance, (2) Traditional CBT, or (3) treatment as usual.

Detailed Description

Despite substantial improvements in diagnosis and treatment, Multiple Sclerosis (MS) remains an unpredictable disease. Although some physicians can make some predictions about expected progression, the variable course of exacerbations makes it almost impossible to predict how MS will develop or affect function over time. As a result, people with MS must learn to live in a state of chronic uncertainty and the ability to tolerate and cope with this kind of uncertainty is central to quality of life with MS. Individuals who require certainty about the future and are not able to tolerate ambiguity are said to be high in a personality trait known as intolerance of uncertainty (IU). There is a significant gap in MS clinical intervention that necessitates attention. An intervention that specifically targets IU, is developed for people recently diagnosed with MS, and can be provided remotely via telehealth can make a significant impact for this population. Study aims include: (1) to determine the efficacy of CBT-UT relative to traditional cognitive behavioral therapy (tCBT) or treatment as usual (TAU) in people diagnosed with MS in the past 3 years; and (2) To increase our understanding of the mechanisms underlying the intervention effects.

Registry
clinicaltrials.gov
Start Date
October 30, 2019
End Date
November 11, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ivan Molton

Professor, School of Medicine: Rehabilitation Medicine: Psychology

University of Washington

Eligibility Criteria

Inclusion Criteria

  • Adults over 18 years of age
  • MS diagnosis using revised McDonald Criteria
  • Able to read, speak, and understand English
  • At least mild psychological distress evidenced by (1) a score of 20 or higher on the Kessler Psychological Distress Scale OR (2) a score greater than or equal to 5 on the Perceived Stress Scale.

Exclusion Criteria

  • Severe cognitive impairment defined as one or more error on the Six-Item Screener
  • Psychiatric condition or symptoms that would interfere with participation, specifically (1) current, active suicidal ideation with current intent to harm oneself, (2) current psychosis, or (3) current mania.

Outcomes

Primary Outcomes

Questionnaire: Level of MS Acceptance as measured by the Acceptance of Chronic Health Conditions, MS Version Questionnaire.

Time Frame: 6 Months

This is a self-reported measure of perceived MS Acceptance. Greater scores represent greater MS Acceptance.

Questionnaire: Level of depression as measured by the Patient Health Questionnaire (PHQ-9).

Time Frame: 6 Months

This is a self-reported measure of perceived depression. Greater scores represent greater levels of depression.

Questionnaire: Level of anxiety as measured by the Global Anxiety Disorder-7 scale (GAD-7).

Time Frame: 6 Months

This is a self-reported measure of perceived anxiety. Greater scores represent greater levels of anxiety.

Secondary Outcomes

  • Demographic: MS Progression Type. Measured by self-reported type of MS.(Baseline)
  • Demographic: Biological Sex. Measured by self-report.(Baseline)

Study Sites (1)

Loading locations...

Similar Trials